Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is a 20% increase over the number of companies cited in the previous quarter.
The citations in the county include:
- The labels of the medical device(s) do not bear a unique device identifier (UDI) that meet the requirements of 801 Subpart B and 21 CFR 830.
- Management with executive responsibility has not reviewed the suitability and effectiveness of the quality system.
- Quality audits have not been performed.
All of the companies cited were involved in either Devices or Drugs sectors.
Of the companies cited, two should take voluntary actions to correct their managing operations (33.3%). Additionally, two companies had to take regulatory and/or administrative actions (33.3%).
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Abraxis Bioscience, LLC | Drugs | 10/06/2023 | Procedures not in writing, fully followed |
Abraxis Bioscience, LLC | Drugs | 10/06/2023 | Equipment to control conditions |
Abraxis Bioscience, LLC | Drugs | 10/06/2023 | input/output verification |
Abraxis Bioscience, LLC | Drugs | 10/06/2023 | Annual visual exams of drug products |
Abraxis Bioscience, LLC | Drugs | 10/06/2023 | Written record of investigation incomplete |
Abraxis Bioscience, LLC | Drugs | 10/06/2023 | Second person sign off |
AnuMed International, LLC | Drugs | 11/07/2023 | Procedures not in writing, fully followed |
AnuMed International, LLC | Drugs | 11/07/2023 | Sanitation--buildings not clean, free of infestation |
AnuMed International, LLC | Drugs | 11/07/2023 | Absence of Written Procedures |
AnuMed International, LLC | Drugs | 11/07/2023 | Scientifically sound laboratory controls |
AnuMed International, LLC | Drugs | 11/07/2023 | Adequate number of batches on stability |
AnuMed International, LLC | Drugs | 11/07/2023 | Prepared for each batch, include complete information |
Neuromechanical Innovations, LLC | Devices | 12/13/2023 | Label to bear a unique device identifier |
Neuromechanical Innovations, LLC | Devices | 12/13/2023 | Management review - defined interval, sufficient frequency |
Neuromechanical Innovations, LLC | Devices | 12/13/2023 | Quality Audit/Reaudit - conducted |
Noraxon USA, Inc. | Devices | 11/30/2023 | Calibration procedures - content |
Signature Formulations, LLC | Drugs | 11/22/2023 | Lack of quality control unit |
Signature Formulations, LLC | Drugs | 11/22/2023 | Absence of Written Procedures |
Signature Formulations, LLC | Drugs | 11/22/2023 | Lab controls established, including changes |
Signature Formulations, LLC | Drugs | 11/22/2023 | Testing and release for distribution |
Signature Formulations, LLC | Drugs | 11/22/2023 | Written program not followed |
Signature Formulations, LLC | Drugs | 11/22/2023 | Procedures to be written and followed |
TAMA Research Corporation | Devices | 10/05/2023 | Records of complaint investigation |
TAMA Research Corporation | Devices | 10/05/2023 | Devices subject to device identification GUDID data submission requirements. |